KOSDAQBiotech & Pharma191420

Tego Science

₩6,170▼ 2.83%2026-11-18 close
Market Cap
₩50B
Turnover
₩28,145,840
Volume
4.5K
Shares out.
8.1M
PER
—
PBR
1.2×
EPS
-₩1,545
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rebounds, losses persist, trial data pending

Tego Science's revenue rose in the second and third quarters of 2026, but operating losses have persisted for five straight quarters, making the topline data for its rotator cuff therapy TPX-115, due January 2027, the next checkpoint.

  1. 1

    Third-quarter 2026 revenue was KRW 3.02 billion, up 86.7% year on year. The company said the consolidation of subsidiary P&P Pharm and higher Kaloderm sales both contributed.

  2. 2

    The third-quarter 2026 operating loss narrowed to KRW 572 million, but the company has posted losses for five straight quarters since the third quarter of 2025. The 2025 operating loss was KRW 4.42 billion, with an operating margin of -74.5%.

  3. 3

    Net losses attributable to controlling shareholders totaled KRW 12.4 billion over the last four quarters. Swings in non-operating items, including derivative valuation losses, have had a large effect on the net loss.

  4. 4

    TPX-115 has completed last-patient follow-up in its Phase 2b trial, with topline results scheduled for January 2027. A change application for the Phase 3 trial plan is pending with the Ministry of Food and Drug Safety.

  5. 5

    Earnings-based multiples cannot be calculated because of net losses over the last four quarters. The price-to-book ratio sits just above 1x.

02

Business structure

Tego Science is a cell culture biotechnology company founded in 2001 and listed on KOSDAQ in 2014. It holds marketing approvals for three products: Holoderm, an autologous cell therapy; Kaloderm, an allogeneic cell therapy; and Rosmir, the only domestic cell therapy approved for wrinkle improvement.

Alphasquare's revenue breakdown shows cell therapy at 77.5%, development services at 12.5%, other at 8.8%, and the three-dimensional skin model at 1.2%, though that breakdown carries no date. In 2022, product sales were about 84% of revenue, trading and cosmetics about 10%, and CDMO about 5%.

Neoderm, a three-dimensional cultured skin model, serves animal-alternative testing, and the company also runs CDMO and contract testing services on its GMP infrastructure. In May 2026 the company acquired a 95.77% stake in P&P Pharm and brought it in as a consolidated subsidiary.

The structure now splits prescription-drug sales, handled by P&P Pharm, from cell therapy R&D, handled by Tego Science. Kaloderm sales are expected to draw on P&P Pharm's network with domestic pharmaceutical companies, with indications extending into orthopedics, plastic surgery, and dermatology. The company describes itself as holding the most domestic cell therapy approvals and indications.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.6B-₩1B−59.0%
2025Q4₩1.4B-₩2.1B−152.1%
2026Q1₩1.2B-₩1.9B−155.8%
2026Q2₩2B-₩1.2B−58.5%
2026Q3₩3B-₩600M−18.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩7.7B₩200M₩300M2.7%0.5%5.9%
2023₩7.8B-₩1.2B-₩2.3B−15.3%−5.0%5.6%
2024₩6.8B-₩2.2B₩3.3B−33.0%6.7%5.7%
2025₩5.9B-₩4.4B-₩7B−74.5%−13.9%55.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a consolidated basis, annual revenue was KRW 7.68 billion in 2022 and KRW 7.77 billion in 2023, which makes 2023 the largest year of the period. Revenue then fell to KRW 6.76 billion in 2024, down 13.0%, and to KRW 5.94 billion in 2025, down 12.1%, which marks two straight years of decline from 2024 through 2025.

The operating result swung from a KRW 210 million profit in 2022 to an operating loss of KRW 1.19 billion in 2023, then widened to KRW 2.23 billion in 2024 and KRW 4.42 billion in 2025. The operating margin moved from 2.7% in 2022 to -15.3% in 2023, -33.0% in 2024, and -74.5% in 2025.

The company attributed the 2025 losses to higher R&D costs tied to the U.S. trial and new clinical programs, lower non-operating income, and derivative valuation losses on convertible bonds.

Net income attributable to controlling shareholders turned to a profit of KRW 3.35 billion in 2024, then to a loss of KRW 7.01 billion in 2025. The company linked the 2025 decline to the absence of large one-off gains such as land sales.

Operating cash flow stayed negative at -KRW 795 million in 2023, -KRW 1.16 billion in 2024, and -KRW 3.07 billion in 2025. The debt ratio rose from 5.7% in 2024 to 55.3% in 2025, with total equity of KRW 50.3 billion and total liabilities of KRW 27.8 billion at year-end 2025.

Quarterly revenue fell from KRW 1.62 billion in the third quarter of 2025 to KRW 1.39 billion and KRW 1.2 billion, then rose to KRW 1.97 billion and KRW 3.02 billion, marking two straight quarters of growth.

Operating losses narrowed each quarter in 2026, from KRW 1.87 billion in the first quarter to KRW 1.15 billion and KRW 572 million. By contrast, the fourth-quarter 2025 net loss attributable to controlling shareholders of KRW 5.04 billion reflected derivative valuation losses. In the first half of 2026, ordinary R&D expenses reached KRW 3.1 billion, up 84% year on year.

05

Industry analysis

According to company materials, Tego Science's domestic rotator cuff treatment market exceeded KRW 500 billion in 2021, with an annual growth rate of 8.6%. The company also published a forecast on its website that the overseas market would reach KRW 13 trillion by 2024.

That forecast dates from around 2021 to 2022, which limits its use as a current size estimate. When it announced FDA clearance of its Phase 2 IND in 2025, the company described a KRW 19 trillion market with no existing treatment.

According to data cited from the Health Insurance Review and Assessment Service, the domestic rotator cuff patient population exceeded 960,000 in 2019. The company describes TPX-115 as the world's first allogeneic fibroblast-based therapy for rotator cuff tears.

Public indicators of industry supply, demand, and cycle position are not clear, so the company's clinical timeline is the central reference for industry judgment.

In Alphasquare's industry comparison table for 89 life sciences and engineering stocks, which shows annual figures with no date, Tego Science ranks 59th by market capitalization and 51st by revenue. It ranks 26th by operating profit, with a smaller loss than the industry average.

The same table places its debt ratio in the 40th range, below the industry average. The P&P Pharm acquisition broadened the sales base, but cell therapy products still account for most of revenue.

06

Outlook

Management said it intends to keep the earnings improvement trend going into the fourth quarter, following the third-quarter 2026 results.

TPX-115 has completed last-patient follow-up in its Phase 2b trial, and topline results from the main analysis are scheduled for release in January 2027 after database lock and statistical analysis.

After review by an independent expert group, the company fixed the number of subjects needed for its Phase 3 trial and has filed a change application with the Ministry of Food and Drug Safety. The company plans to start Phase 3 once that change is approved.

In the United States, the TPX-115 Phase 2 trial is enrolling about 60 patients, with an overall duration of roughly 15 months. The wrinkle therapy TPX-121 is also moving through a Phase 2/3 IND application process.

The company also plans to continue developing TPX-124, a hair growth protein therapy, and TPX-125, a gene cell therapy for a rare genetic skin disease. P&P Pharm plans to strengthen Kaloderm sales and widen the medical specialties that use it.

However, first-half 2026 R&D expenses rose sharply year on year, so clinical costs remain a burden on reported results. Derivative valuation results can swing with the share price and interest rates, and they remain a source of quarterly net income volatility.

The next checkpoints are the January 2027 topline results, the approval status of the Phase 3 plan change, and full-year results in the 2026 annual report.

07

Valuation

PER
—
PBR
1.2×
ROE
-24.6%
EPS
-₩1,545
BPS
₩5,394
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, earnings-based multiples are not meaningful. Valuation therefore leans more on net assets and pipeline progress than on earnings.

The price-to-book ratio is slightly above 1x, a modest premium to net assets attributable to controlling shareholders at the end of 2025. The share price remains well below its 52-week high. The company pays no confirmed dividend, a large gap relative to the industry average dividend level.

Derivative valuation results and convertible bond liabilities affect the capital structure, which adds volatility to any reading of net asset value. In the industry comparison table, the price-to-book figure is hard to compare directly because many companies in the sector are loss-making.

The full-year profit and debt structure confirmed in the 2026 annual report is the next reference point for valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Quarterly revenue up two straight quarters

Revenue rose from the prior quarter in both the second and third quarters of 2026. The company disclosed that cumulative third-quarter revenue reached KRW 6.19 billion, up 36% year on year.

The consolidation of P&P Pharm and higher Kaloderm sales were cited as growth drivers, which supports the case for a stronger sales base in its core cell therapy business.

TPX-115 topline data due January 2027

TPX-115 has completed last-patient follow-up in its Phase 2b trial, and the main results are scheduled for January 2027 after database lock and statistical analysis. The data would inform the decision to move into Phase 3. The company fixed the Phase 3 subject count after review by an independent expert group. The release itself would serve as a checkpoint on pipeline value.

P&P Pharm adds a sales channel

Since the acquisition, the consolidation of P&P Pharm has been reflected in third-quarter revenue. P&P Pharm is described as having more than 25 years of pharmaceutical sales experience. The split assigns sales to P&P Pharm and R&D to Tego Science. Reports say Kaloderm's medical specialties could expand into orthopedics and plastic surgery.

09

Bear factors

Operating losses for five straight quarters

The company has posted operating losses for five straight quarters, from the third quarter of 2025 through the third quarter of 2026. The company attributed the larger operating loss to clinical trial costs. Losses have narrowed each quarter, but no timeline for a return to operating profit has been given.

Derivative losses swing net results

The fourth-quarter 2025 net loss attributable to controlling shareholders of KRW 5.04 billion reflected derivative valuation losses that increased non-operating costs. First-half 2026 derivative valuation losses on convertible bonds were reported at about KRW 4.5 billion.

The company says these are non-cash accounting losses. Even so, their size makes net results harder to forecast.

Two years of revenue decline and cash outflows

Revenue declined in both 2024 and 2025, and the 2025 operating margin was -74.5%. Operating cash flow was negative in each year from 2023 through 2025. The debt ratio rose to 55.3% at the end of 2025 from 5.7% in 2024. With losses continuing, cash generation has not yet been demonstrated.

10

Risk factors

Clinical outcome risk

If TPX-115's Phase 2b results fall short of the bar for Phase 3, the pipeline value could be revised. The Phase 3 plan change requires approval from the Ministry of Food and Drug Safety, and no approval date has been disclosed. The U.S. Phase 2 trial is also ongoing, so results on both sides could affect the outlook. Delays in the clinical timeline could extend the cost burden.

Capital structure and dilution risk

Convertible bonds issued in May 2025 have produced derivative valuation results that drive swings in net income. With the debt ratio at 55.3%, financing costs and repayment obligations need monitoring.

At its March 2026 annual meeting, the company approved an articles amendment to strengthen its shareholder return policy. Conversions of the bonds could increase the number of shares outstanding.

Revenue concentration and float

Cell therapy accounts for 77.5% of revenue, so the business depends heavily on one product line. The largest shareholder group holds 41.79% of shares, and the free float ratio is 56.62%. Foreign ownership is only 1.46%. Under this structure, thin trading volume could amplify share price moves.

11

What to watch next

  1. January 2027

    Topline results from the TPX-115 Phase 2b trial. This is the key checkpoint for the Phase 3 decision and pipeline value.

  2. After November 2026, date not set

    Whether the Ministry of Food and Drug Safety approves the Phase 3 trial plan change. Approval would allow the company to start Phase 3.

  3. Late March 2027

    Filing deadline for the 2026 annual report. It will show full-year 2026 results, fourth-quarter results, and notes on debt and derivatives.

  4. Mid-May 2027

    Filing deadline for the first-quarter 2027 report. It will show whether the operating loss keeps narrowing and how R&D spending trends.

12

Overall view

Tego Science's third-quarter 2026 revenue was KRW 3.02 billion, up 86.7% year on year, and its operating loss narrowed to KRW 572 million. However, the company has posted operating losses for five straight quarters since the third quarter of 2025, and the 2025 operating margin was -74.5%.

Revenue declined in both 2024 and 2025, and operating cash flow was negative from 2023 through 2025. Net losses attributable to controlling shareholders totaled KRW 12.4 billion over the last four quarters, with derivative valuation results causing large swings.

The P&P Pharm acquisition split sales and R&D roles, and topline data for TPX-115, the core pipeline asset, are scheduled for January 2027. The next checkpoints are the January 2027 clinical results, the approval status of the Phase 3 plan change, and the full-year profit and debt structure in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. alphabiz.co.kr
  2. tegoscience.com
  3. comp.wisereport.co.kr
  4. kr.investing.com
  5. etoday.co.kr
  6. goinsider.kr
  7. alphasquare.co.kr
  8. m.news.nate.com
  9. etoday.co.kr
  10. m.news.nate.com
  11. comp.wisereport.co.kr
  12. investing.com
  13. en.edaily.co.kr
  14. jobkorea.co.kr
  15. judal.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis